Soligenix Inc. Warrant
SNGXW
NASDAQ Capital Market0.01
USD
+0.00
- -
Soligenix Inc. Warrant
SNGXW
(NASDAQ Capital Market)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Soligenix, Inc. Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, operating through two segments: Specialized BioTherapeutics, which targets orphan diseases including cutaneous T-cell lymphoma via HyBryte (synthetic hypericin-based photodynamic therapy), psoriasis via SGX302 (same active ingredient as HyBryte), oral mucositis via SGX942 (innate defense regulator), and Behçet's Disease via SGX945 (same active ingredient as SGX942) and dusquetide; and Public Health Solutions, which develops vaccines and therapeutics such as RiVax for ricin toxin exposure, thermostabilized filovirus vaccines including MarVax for Marburg and SuVax for Sudan Ebola, and CiVax for COVID-19, incorporating the proprietary ThermoVax heat stabilization platform technology. The company, founded in 1987 and headquartered in Princeton, New Jersey, conducts preclinical through Phase 3 clinical studies with specialized expertise in orphan drug designations, Fast Track status, and adaptive trial designs, targeting patients with rare oncology, inflammatory, and infectious diseases primarily in the United States, Europe, and Asia. Recent developments include the initiation of a confirmatory Phase 3 trial for HyBryte in cutaneous T-cell lymphoma in December 2024 supported by a $2.6 million FDA Orphan Products grant showing positive interim outcomes in 75% of early-stage patients; the start of a Phase 2 trial of SGX945 (dusquetide) for Behçet's Disease in November 2024 following FDA Orphan Drug and Fast Track designations; a strategic manufacturing partnership with Sterling Pharma Solutions announced in October 2024 for U.S. expansion of synthetic hypericin production, validated by successful production in July 2025; full repayment and termination of its Loan and Security Agreement with Pontifax Medison in February 2025; a $7.5 million public offering closed in September 2024; a 1-for-16 reverse stock split effective June 2024; FDA Orphan Drug designations in April 2025 for dusquetide in Behçet's Disease and previously for MarVax and SuVax; formation of European and Behçet's Disease medical advisory boards; and European and Hong Kong patents for improved synthetic hypericin production.